Montes AF, et al. - Researchers evaluated the effect of FOLFIRI-aflibercept in 78 patients with metastatic colorectal cancer with or without bevacizumab at six hospitals from the Galician Research Group on Digestive Tumors (GITuD) network. Patients had good general status, tumors were mostly RAS-mutant (75.6%), synchronous (71.8%), and left-sided (71.8%). Longer PFS was noted for metachronous tumors vs synchronous tumors (11.0 vs 5.0 months), and for left-colon tumors (7.0 vs 3.0 months). The disease control rate of 70.5%; neutropenia (15.3%), asthenia (10.3%), diarrhea and mucositis (6.4% each) were identified as the most common grade 3/4 toxicities. Data revealed dysphonia in 39.7% of patients and grade 3 hypertension in 3.8%. Multivariate analysis revealed a significant association of the development of hypertension (any grade) with a reduced risk of progression. Primary tumor location, RAS-mutant status, first-line treatment or primary tumor surgery were not seemed to influence the survival outcomes.